Literature DB >> 19496624

In vitro selection of RNA aptamers derived from a genomic human library against the TAR RNA element of HIV-1.

Marguerite Watrin1, Frederike Von Pelchrzim, Eric Dausse, Renée Schroeder, Jean-Jacques Toulmé.   

Abstract

The transactivating responsive (TAR) element is a RNA hairpin located in the 5' untranslated region of HIV-1 mRNA. It is essential for full-length transcription of the retroviral genome and therefore for HIV-1 replication. Hairpin aptamers that generate highly stable and specific complexes with TAR were previously identified, thus decreasing the level of TAR-dependent expression in cultured cells [Kolb, G., et al. (2006) RNA Biol. 3, 150-156]. We performed genomic SELEX against TAR using a human RNA library to identify human transcripts that might interact with the retroviral genome through loop-loop interactions and potentially contribute to the regulation of TAR-mediated processes. We identified a genomic aptamer termed a1 that folds as a hairpin with an apical loop complementary to five nucleotides of the TAR hexanucleotide loop. Surface plasmon resonance experiments performed on a truncated or mutated version of the a1 aptamer, in the presence of the Rop protein of Escherichia coli, indicate the formation of a highly stable a1-TAR kissing complex. The 5' ACCCAG loop of a1 constitutes a new motif of interaction with the TAR loop.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496624     DOI: 10.1021/bi802373d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Triggering nucleic acid nanostructure assembly by conditional kissing interactions.

Authors:  Laurent Azéma; Servane Bonnet-Salomon; Masayuki Endo; Yosuke Takeuchi; Guillaume Durand; Tomoko Emura; Kumi Hidaka; Eric Dausse; Hiroshi Sugiyama; Jean-Jacques Toulmé
Journal:  Nucleic Acids Res       Date:  2018-02-16       Impact factor: 16.971

2.  Emerging Technologies for the Treatment of COVID-19.

Authors:  Hossein Aghamollaei; Rahim Sarvestani; Hamid Bakherad; Hamed Zare; Paul C Guest; Reza Ranjbar; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  HIV-1 drug discovery: targeting folded RNA structures with branched peptides.

Authors:  Jessica E Wynn; Webster L Santos
Journal:  Org Biomol Chem       Date:  2015-06-07       Impact factor: 3.876

Review 4.  Genomic SELEX: a discovery tool for genomic aptamers.

Authors:  Bob Zimmermann; Ivana Bilusic; Christina Lorenz; Renée Schroeder
Journal:  Methods       Date:  2010-06-09       Impact factor: 3.608

5.  A boost for the emerging field of RNA nanotechnology.

Authors:  Girish C Shukla; Farzin Haque; Yitzhak Tor; L Marcus Wilhelmsson; Jean-Jacques Toulmé; Hervé Isambert; Peixuan Guo; John J Rossi; Scott A Tenenbaum; Bruce A Shapiro
Journal:  ACS Nano       Date:  2011-05-24       Impact factor: 15.881

6.  HAPIscreen, a method for high-throughput aptamer identification.

Authors:  Eric Dausse; Saïd Taouji; Laetitia Evadé; Carmelo Di Primo; Eric Chevet; Jean-Jacques Toulmé
Journal:  J Nanobiotechnology       Date:  2011-06-03       Impact factor: 10.435

7.  Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects.

Authors:  Zhangang Xiao; Jing Shen; Lin Zhang; Mingxing Li; Wei Hu; Chihin Cho
Journal:  Oncol Lett       Date:  2018-01-09       Impact factor: 2.967

Review 8.  Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets.

Authors:  Didier Meseure; Kinan Drak Alsibai; Andre Nicolas; Ivan Bieche; Antonin Morillon
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

9.  Aptamer-based therapeutics: new approaches to combat human viral diseases.

Authors:  Ka-To Shum; Jiehua Zhou; John J Rossi
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-25

10.  Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy.

Authors:  Chi Han Li; Yangchao Chen
Journal:  Curr Genomics       Date:  2015-10       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.